Business
Aethlon Medical is developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at cancer, life-threatening viral infections, organ transplantation, and other unmet needs.
Aethlon remains a clinical-stage Hemopurifier company with no revenue in the local annual row and a going-concern warning.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage Hemopurifier deviceNote
- Revenue — No revenue in local annual rowNote
- Profitability — Net loss widened to $13.4MWatch
- Cash burn — Free cash flow improved to -$7.6MNote
- Balance sheet — Equity fell 11.1% to $5.1MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — FY2024 Altman-Z distressWatch
Leadership changes
From AETHLON MEDICAL INC's own filings, the day they're filed.
- James B. Frakes · Chief Executive Officer · appointmenteff. 2024-10-03
- Guy F. Cipriani · Chief Operating Officer · departureeff. 2024-10-03
- Charles J. Fisher Jr · departureeff. 2023-11-27
Latest filings
- 8-K · Company announcement2026-10-01
- 8-K · Company announcement2026-09-17
- 8-K · Company announcement2026-09-15
- DEF 14A · Annual proxy (pay & governance)2026-09-01
- 8-K · Company announcement2026-08-31
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AETHLON MEDICAL INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.